These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33002889)

  • 1. Risk Factors for Recurrence in Pancreatic Neuroendocrine Tumor and Size as a Surrogate in Determining the Treatment Strategy: A Korean Nationwide Study.
    Kwon W; Jang JY; Song KB; Hwang DW; Kim SC; Heo JS; Choi DW; Hwang HK; Kang CM; Yoon YS; Han HS; Park JS; Hong TH; Cho CK; Ahn KS; Lee H; Lee SE; Jeong CY; Roh YH; Kim HJ;
    Neuroendocrinology; 2021; 111(8):794-804. PubMed ID: 33002889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factor Analysis of Lymph Node Metastasis for Rectal Neuroendocrine Tumors: Who Needs a Radical Resection in Rectal Neuroendocrine Tumors Sized 1-2 cm?
    Choi JS; Kim MJ; Shin R; Park JW; Heo SC; Jeong SY; Park KJ; Ryoo SB
    Ann Surg Oncol; 2024 Apr; 31(4):2414-2424. PubMed ID: 38194045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.
    Kim J; Hong SS; Kim SH; Hwang HK; Kang CM
    World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
    Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K
    Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
    Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
    J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases.
    Dong DH; Zhang XF; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM;
    J Surg Oncol; 2019 Dec; 120(7):1071-1079. PubMed ID: 31571225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.
    Wong J; Fulp WJ; Strosberg JR; Kvols LK; Centeno BA; Hodul PJ
    Am J Surg; 2014 Nov; 208(5):775-780. PubMed ID: 24997491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant potential of small pancreatic neuroendocrine neoplasm and its risk factors: A multicenter nationwide study.
    Paik WH; Lee HS; Lee KJ; Jang SI; Lee WJ; Hwang JH; Cho CM; Park CH; Han J; Woo SM; Jeong S; Chon HK; Kim TN; Lee JK; Han JH; Yoon JH; Kim YT; Cho JH
    Pancreatology; 2021 Jan; 21(1):208-214. PubMed ID: 33281058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of recurrence after surgery based on preoperative MRI features in patients with pancreatic neuroendocrine tumors.
    Han S; Kim JH; Yoo J; Jang S
    Eur Radiol; 2022 Apr; 32(4):2506-2517. PubMed ID: 34647178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
    Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
    JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs).
    Jung JG; Lee KT; Woo YS; Lee JK; Lee KH; Jang KT; Rhee JC
    Medicine (Baltimore); 2015 Jul; 94(26):e983. PubMed ID: 26131843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
    Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
    J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
    Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
    Kuo EJ; Salem RR
    Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of systemic immune-inflammation index in patients with nonfunction pancreatic neuroendocrine tumor undergoing surgical resection.
    Chen G; Liu L; Tan C; Tan Q; Chen Y; An X; Liu X; Wang X
    Cancer Med; 2024 Apr; 13(7):e7114. PubMed ID: 38553949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis.
    Sahara K; Tsilimigras DI; Mehta R; Moro A; Paredes AZ; Lopez-Aguiar AG; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Poultsides GA; Makris E; Cho C; Beems M; Dillhoff M; Maithel SK; Endo I; Pawlik TM
    Ann Surg Oncol; 2020 Apr; 27(4):1203-1212. PubMed ID: 31838609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role and predictors of lymph node involvement in pancreatic neuroendocrine tumors.
    Ren SJ; Tan QQ; Cao D; Ke NW; Liu XB; Wang X
    Eur J Radiol; 2023 May; 162():110772. PubMed ID: 36940547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.